Aricò, M., Conter, V., Valsecchi, M., Masera, G. (2003). Importance of minimal residual disease testing during the second year of disease: still no answer?. JOURNAL OF CLINICAL ONCOLOGY, 21(23), 4463-4464 [10.1200/JCO.2003.99.093].

Importance of minimal residual disease testing during the second year of disease: still no answer?

VALSECCHI, MARIA GRAZIA;
2003

Articolo in rivista - Articolo scientifico
Prognosis; Randomized Controlled Trials as Topic; Antineoplastic Agents; Time Factors; Polymerase Chain Reaction; Neoplasm, Residual; Disease-Free Survival; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Humans; Bone Marrow
English
1-dic-2003
21
23
4463
4464
none
Aricò, M., Conter, V., Valsecchi, M., Masera, G. (2003). Importance of minimal residual disease testing during the second year of disease: still no answer?. JOURNAL OF CLINICAL ONCOLOGY, 21(23), 4463-4464 [10.1200/JCO.2003.99.093].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/21505
Citazioni
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
Social impact